Introduction
Currently marketed epidermal growth factor receptor inhibitors (egfris) have been associated with high rates of dermatologic toxicity.
Methods
We formally reviewed the literature at medline and embase. Additional searches were conducted using Internet search engines. Studies were eligible if they were randomized controlled clinical trials of egfris, specifically cetuximab and panitumumab, in which at least one arm consisted of a non-egfri treatment and rash safety data were reported. The random effects method was used to pool differences in incident rash rates. Results are summarized as differences in incident rash (egfri therapy rate minus the non-egfri therapy rate) with corresponding 95% confidence intervals (cis) for all severity grades of rash and for grades 3 and 4 rash.
Results
Sixteen studies met the initial inclusion criteria of randomized controlled trials comparing egfri with non-egfri therapy. Seven publications that provided information on all severity grades of rash were found to have an overall difference in incident rash rate of 0.74 (95% ci: 0.68 to 0.81; p < 0.01). Thirteen studies that reported the incidence of grades 3 and 4 rash showed an overall difference in the incident rash rate of 0.12 (95% ci: 0.09 to 0.14; p < 0.01) between egfri and non-egfri therapy. Sensitivity analyses showed that the results were generally robust, but sensitive to small samples.
Conclusions
Results quantify the difference in rash rates between egfri and non-egfri therapy.
Many studies have reported dermatologic toxicities resulting from treatment with egfris. One study pooled the incident rash rates from a number of single-arm radiotherapy studies 12 . However, differences in the rates of rashes reported in studies comparing egfri therapy with treatment not using an egfri (for example, chemotherapy, or best supportive care, or both) have not been systematically quantified. The present analysis used meta-analytic techniques to systematically pool rash event rates so as to determine risk differences between egfris and non-egfri agents.
METHODS
We conducted a formal systematic review of medline and embase for the period January 2005 to August 2009. Search criteria included randomized comparative clinical trials, English-language literature, and search terms (mesh, text words) including "egfr inhibitor," "cetuximab," "panitumumab," and "cancer/oncology," "rash/egfr inhibitor rash." Additional literature searches using the same search terms were conducted using the Google and Google Scholar Internet search engines. These searches focused on the terms "cetuximab/panitumumab" and "rashes." The search was not limited to a particular disease site. Abstracts for each article located were reviewed.
Studies were defined as eligible if they were comparative clinical trials of egfr is, specifically cetuximab or panitumumab, in which at least one arm of the study did not include a therapy that targeted egfr (for example, chemotherapy or best supportive care) and in which safety data for dermatologic toxicity were reported. Studies involving radiotherapy or non-egfri monoclonal antibody agents (for example, bevacizumab, erlotinib) were excluded from the analysis because of a different mechanism of action. Conference abstracts (for example, those from the American Society of Clinical Oncology) were not included because of the incomplete and preliminary nature of data abstracts. Editorials or commentaries, observational studies, quality-of-life studies, and review articles were also excluded from the analysis.
Abstracts of studies found through the foregoing search were independently reviewed by two reviewers for appropriateness (namely, original comparative clinical trial of egfri therapy compared with non-egfri treatment, including rash outcomes). Once a study was deemed to be appropriate, study data were extracted.
The primary outcome was the incidence of two classifications of rash: all severity grades, and grades 3 and 4. Because rash has historically been characterized using a number of different terms (acneiform rashes, acne-like rashes, skin toxicity, skin rashes, and rashes in general, for instance), all rash classifications were extracted for analysis. Detailed investigation showed that rash was often labelled using the term "rash" or "skin rash," but could also be defined according to the standard toxicity severity grading as defined by the ctcae 7 . Rash definitions in the individual studies were reviewed in detail. The number of patients with events was used as the numerator. Differences in rash rates were reported for all diseases (for example, nsclc, crc, and other solid tumour types). Data were extracted independently by the two reviewers, and any discordance was discussed and reconciled.
Results are reported as the difference in the rate of rash: specifically, the rate of rash reported for egfris minus the rate of rash reported for non-egfri therapy. Numerators and denominators were extracted. The analysis was performed in the RevMan program (Review Manager, version 5.0: The Nordic Cochrane Centre, Copenhagen, Denmark) using a random-effects model and Mantel-Haenszel methods. Results are summarized as the mean difference 
RESULTS
Sixteen studies met the initial inclusion criteria of randomized controlled trials of egfris. Three studies were excluded from the analysis: one study used an egfri in both arms 13 , one did not present rash rates according to either grades 3 and 4 criteria or allgrades criteria 14 , and one study was a duplicate of another study 15 . Thus thirteen studies were eligible for inclusion in the meta-analysis ( Table ii) .
Most of the studies examined cetuximab in mcrc (n = 7), nsclc (n = 3), head-and-neck cancer (n = 2), and pancreatic cancer (n = 1). One study included in the analysis evaluated the efficacy and safety of panitumumab. Seven publications provided information on the incidence of all grades of rash (Table iii) 9, 16, 17, 19, 23, 25, 27 . The difference between egfris and non-egfris in overall incidence rate for all severity grades of rash was 0.74 (95% ci: 0.68 to 0.81; p < 0.01; chi-square: 42.21, p < 0.001). The difference in the rates of rash between egfri and non-egfri therapies ranged between 0.52 and 0.86.
Thirteen publications provided information on grades 3 and 4 rashes ( Table iv) . The overall difference in the rates of grades 3 and 4 rash between egfri and non-egfri therapy was 0.12 (95% ci: 0.09 to 0.14; p < 0.01; chi-square: 48.13, p < 0.001). The risk difference ranged between 0.02 and 0.40. When reporting grades 3 and 4 rates, six of thirteen studies (46%) indicated that no grade 4 rash reactions had occurred.
For the sensitivity analysis related to rashes overall, we examined rash rate differences in mcrc patients (five studies 9, 18, 19, 23, 25 ), in studies with active comparators (five studies 16, 17, 19, 23, 25 ) , and in studies with best supportive care as the comparator (two studies 9, 18 , Table v) .
For the sensitivity analysis related to grades 3 and 4 rashes, we examined the rash differences in studies reporting grade 4 reactions (seven studies 9, 17, 19, 20, [23] [24] [25] ), in studies with active comparators (eleven studies 16, 17, [19] [20] [21] [22] [23] [24] [25] [26] [27] ), in studies with best supportive care as the comparator (two studies 9, 18 ), in studies evaluating crc patients only (seven studies 9, 18, 19, 23, [25] [26] [27] ), in studies evaluating nsclc patients only (three studies 17, 21, 22 ) , and in studies with best supportive care as a comparator (two studies 9, 18 , Table v ).
DISCUSSION
The results from this systematic review provide a pooled value for the difference in the rates of rash associated with therapies using egfris and not using egfris in patients diagnosed with a number of solid tumours. Studies were heterogeneous, with variation in rash definition, sample size, disease site, and nonegfri comparator.
Sensitivity analyses were conducted by removing studies from the overall pooled analyses. The sensitivity analyses were limited by the number of studies available for subgroup analyses and by the availability of rash rates. Examination of subpopulations in the included studies showed generally similar rash rate differences for grades 3 and 4 reactions when studies with only crc patients or with only active comparators were included. By contrast, studies examining patients with nsclc showed a rate difference with respect to grades 3 and 4 rash between egfri and nonegfri therapies that was higher than the rate difference overall (0.20 vs. 0.12 overall). This difference may be related to the small number of combinable studies or to a disease site that may be associated with a risk of developing rash. Results also showed that the difference in rates of rash was slightly lower in studies in which no grade 4 rashes were reported during the trial (0.09 vs. 0.12 overall).
Examination of all severity grades of rash showed that differences were relatively similar to those for the overall study sample, with rash rates ranging between 0.70 and 0.78. Studies in which a non-egfri comparator was considered best supportive care reported higher differences in rash rates (0.82 vs. 0.74 overall). With active comparators, that difference declined (0.74 overall vs. 0.70). More studies had active comparators than inactive comparators, but the sample sizes in the studies with inactive comparators were large and thus contributed to the overall value of the pooled estimate.
It is important to note that, of the thirteen clinical trials included in the analysis, twelve were based on the use of cetuximab; only one trial reported on the use of panitumumab. Despite a similar mechanism of action, the results as presented here should arguably be considered to be applicable only to cetuximab.
We pooled rash rates for cetuximab and panitumumab because those egfris met the inclusion requirements and because those two agents have the same mechanism of action in that they target the extracellular domain of egfr. Erlotinib and gefitinib target tyrosine kinase and have a different anatomical therapeutic chemical classification. Bevacizumab, although in the same class as cetuximab and panitumumab, is an inhibitor of vascular endothelial growth factor.
Discontinuation rates because of adverse events or rashes were not reported consistently in the included studies. Only one study provided a rate of discontinuation because of rash (4%) 26 ; others reported discontinuations related to egfri reactions-for example, infusion-related or general toxicity 13, 17, 23 . Consequently, a systemic review of discontinuation rates could not be conducted, and the pooled difference in rates of discontinuation because of rash a Defined as the presence of one or more incidents of rash or desquamation, dry skin, nail changes, or other skin toxicity of all grades according to the National Cancer Institute's Common Toxicity Criteria, version 2.0. b Defined as any event described as rash, rash pustular, rash erythematous, dermatitis acneiform, dermatitis exfoliative, rash papular, rash pruritic, rash generalized, rash macular, rash maculopapular, acne, dry skin, acne pustular, and skin desquamation. c Acne, acne pustular, dermatitis acneiform, dry skin, erythema, folliculitis, pruritus, rash, rash erythematous, rash follicular, rash generalized, rash macular, rash maculopapular, rash papular, rash pruritic, rash pustular, skin exfoliation, skin hyperpigmentation, telangiectasia, xerosis. d Includes rash, rash pustular, rash erythematous, dermatitis acneiform, dermatitis exfoliative, rash papular, rash pruritic, rash generalized, rash macular, rash maculopapular, acne, acne pustular, skin desquamation, and dry skin. e Acne pustular, acne, celulitis, dermatitis acneiform, dry skin, erysipelas, erythema, face edema, folliculitis, growth of eyelashes, hair growth abnormal, hypertrichosis, nail-bed infection, nail-bed inflammation, nail disorder, nail infection, paronychia, pruritus, rash erythematous, rash follicular, rash generalized, rash macular, rash maculopapular, rash papular, rash pruritic, rash pustular, rash, skin exfoliation, skin hyperpigmentation, skin necrosis, staphylococcal scalded skin syndrome, telangiectasia, wound necrosis, and xerosis. f Included these terms from the Medical Dictionary for Regulatory Activities, version 8.1: acne, acne pustular, celulitis, dermatitis acneiform, dry skin, erysipelas, erythema, face edema, folliculitis, growth of eyelashes, hair growth abnormal, hypertrichosis, nail bed infection, nail bed inflammation, nail disorder, nail infection, paronychia, pruritus, rash, rash erythematous, rash follicular, rash generalized, rash macular, rash maculopapular, rash popular, rash pruritic, rash pustular, skin exfoliation, skin hyperpigmentation, skin necrosis, staphylococcal scalded skin syndrome, telangiectasia, wound necrosis, xerosis. bsc = best supportive care; Gr = grade; nr = not reported; folfox4 = oxaliplatin-leucovorin-5-fluorouracil; folfiri = folinic acid-5-fluorouracilirinotecan; oxmdg = oxaliplatin-leucovorin-5-fluorouracil; xelox = capecitabine-oxaliplatin; nsclc = non-small-cell lung cancer; mdra = Medical Dictionary for Regulatory Activities; na = not available. could not be determined. Discontinuation may be an important outcome to provide, because it may act as a surrogate outcome for the effect and importance of rash for the patient. Indeed, in one survey of oncology practices, 76% of physicians reported having to temporarily withhold treatment, 60% reported dose reductions, and 32% reported having to discontinue treatment because of rash 6 . Post-radiotherapy radiation dermatitis was not included in this analysis of chemotherapy agents. One trial comparing radiation alone with radiation plus cetuximab in squamous cell carcinoma of the head and neck was found 28 , but it was excluded from the meta-analysis because the comparator group did not receive chemotherapy. The rate of grades 3-5 radiation dermatitis was higher in the radiation plus cetuximab arm (23% vs. 18%), but the difference was found to be statistically nonsignificant. Other studies (case series) have suggested that the combination of cetuximab and radiotherapy in actual practice resulted in even higher rates of moderate-to-severe skin toxicity, with estimates as high as 49% for the occurrence of grades 3 and 4 rashes in head-and-neck patients receiving cetuximab plus radiotherapy [29] [30] [31] [32] . A recent pooled analysis of mostly noncomparative studies reported incident high-grade radiation dermatitis rates of 31.3% in patients receiving egfris and radiation 12 . However, a larger retrospective analysis of 115 patients with locally advanced head-and-neck cancer receiving radiation and cetuximab showed grades 3 and 4 radiation dermatitis occurring in 23% of patients 10 . That rate was similar to the rate reported by Bonner et al. 28 . The mechanism of action for skin toxicity with radiotherapy and egfris is unknown 30 .
Prophylaxis was not routinely discussed in the studies and was therefore not pooled. The search identified two studies that used an egfri in combination with bevacizumab for mcrc 33, 34 . Bevacizumab is a monoclonal antibody targeting the vascular endothelial growth factor 35 . All other studies used chemotherapy or best supportive care. The bevacizumab studies were excluded from the pooling because skin toxicities that would confound the difference in rash rates with egfris have also been associated with bevacizumab 35 .
It is important to emphasize that the term "rash" was reported in an inconsistent manner-namely, different labels were used for rash in the included studies. Some studies used the label "acneiform rash" when rash was actually a composite of various dermatologic toxicities 17 ; other studies provided many different labels for rash (for example, skin rash, rash, acneiform 19, 26 ). We believe that these labelling differences are attributable to inconsistent reporting of rash by investigators, given that there is no common definition for egfri-induced rash. Specifically, the term "acneiform" should be avoided, because it describes rashes related to acne, which is a type of rash different from the rashes arising from egfris 36 . Given the terms used in each study, careful dissection and consultation with a dermatologist were required to identify event rates for all rashes and for grades 3 and 4 rashes for appropriate pooling. Challenges were associated with definitions (for example, "rash," "acneiform"-ctcae definitions, but which version?) and with grades (for example, typical ctcae gradations, but which version?). The potential for "misclassification" of a rash definition may have influenced the overall rates of rash. The potential for "misclassification" of a grade definition may have influenced the difference reported for severe rashes (that is, grades 3 and 4), but should not have affected overall rash rates.
In clinical trials and post-marketing studies, careful recording and standardized labelling of rashes would ensure that rash rates can be clearly identified. Location of rash and total body surface area affected by rash were not reported in the included studies, but would provide important information on the scope of rashes. The ctcae grading of rash does not take into account the localization of rash on the body; it focuses strongly on body surface area coverage. Because of the relatively localized nature of egfriinduced rashes, the ctcae grading system may not be appropriate for this type of rash and may underreport rash severity. Adherence to standard terminology or definitions-and adoption of their systematic use-is recommended, as is proper recording.
With the increased use of egfris, skin rashes and their incidence and management have recently received attention 6, [37] [38] [39] . Current anti-egfr therapies can adversely inhibit non-tumour egfr in the skin, which may lead to skin toxicities. It has been reported that rashes typically resolve without treatment after discontinuation of anti-egfr therapy 4 and that they are seldom fatal 40 . Despite the seriousness of rash, a number of studies have found a positive association between severity of rash and increased survival 4, 9, 38 , indicating that rash associated with egfris can be a predictor of survival 38 .
Publications examining rashes associated with egfris have commented on the effect of a rash on a patient's quality of life 12, 41 . It is hypothesized that, if toxicity becomes severe, there is a chance that patients would not continue treatment and thus jeopardize the possibility of improved survival outcome. However, there is some conflicting evidence. Tejwani and colleagues 12 hypothesized that patients were willing to tolerate rashes because, with some agents, rashes were associated with improved survival and considered a necessary part of treatment in a situation with no other options. Osio and colleagues 42 conducted a retrospective analysis of the chronic cutaneous effects of these egfris and impact of rash on quality of life. In a small sample of patients (n = 16), investigators found that all patients reported cutaneous adverse events, with 38% being of severity grades 1 and 2. Dose reductions or discontinuation of egfris were required in 6 patients (38%). In 6 patients (38%), rash was reported to be associated with an impact on quality of life 42 . Most of the instruments used to determine quality of life in these studies are considered to be general qualityof-life instruments for oncology, including the Functional Assessment of Cancer Therapy (fact) and the European Organization for Research and Treatment of Cancer qlq-C30, although specific dermatology instruments (the Dermatology Life Quality Index, for instance) have been used 42 . General instruments measuring quality of life may not be sensitive to changes associated with dermatologic conditions. A precedent for creating quality-of-life tools with a focus on an adverse events has been set with the creation of the fact-Neutropenia 43 . A quality-of-life instrument specific to egfri-related rash may be useful.
As long as efficacy is maintained, agents that do not cause skin toxicity would be preferable over agents that do. There is some evidence that newer egfris with intermediate binding affinity are on the horizon; such agents may be able to reduce skin-related toxicities while maintaining efficacy 44, 45 .
Substantial resources and costs are associated with the outpatient and inpatient management of egfri-induced rashes 6, 40, 41, 46, 47 . Once risk differences are determined, the costs of rash can be calculated. Here, the costs of rash-associated treatment and hospitalization were determined using resource utilization from the published literature and costs based on 2009 U.S. Medicaid and Medicare numbers. We determined that the cost of treatment may range from US$500 (grade 3) to US$15,000 (grade 4) per rash episode, including the cost of hospitalization. The result could be a budget impact of approximately US$20 million per annum for patients treated with an egfri in mcrc, based on a difference of 12% in grades 3 and 4 rash as derived from the present study (Chan B. Personal communication) 48 .
CONCLUSIONS
Skin toxicities are a common adverse drug reaction seen with egfris such as cetuximab and panitumumab. Compared with non-egfri therapy, egfri therapy carries an overall risk difference of 74% for rashes of all severities and of 12% for grades 3 and 4 rashes. Standardization of rash definitions is recommended to facilitate appropriate pooling of data.
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